PROTALIX BIOTHERAPEUTICS, INC. (PLX)

[Kronberg]

Hi Spideyboy. In my opinion the company has problems communicating with us shareholders.They did not announce an extension of Bright study and EXPANDED ACCESS POLICY.Although both of these events is clearly a positive development. CF P2 results were published in april 2017.Since then, the company has not bothered to provide any information about PRX-110 except that its appeal to CF Foundation was rejected.Perhaps this is one of the reasons our Market Cap is $72M today.Protalix has a very good chance of PRX-102 success but this is IMO not accounted in the share price.The next events IMO can seriously increase the share price

1.another partnership
2.obtaining significant milestones from Chiesi
3.suspension of the Bright study for the apparent advantage
4.EMA and FDA clearance
5.buyout